EODData

MEMBERSHIP REGISTER LOG IN

AMEX, CATX: Perspective Therapeutics Inc

07 Nov 25 10:46
LAST:

2.140

CHANGE:
 0.09		OPEN:
2.260		HIGH:
2.260		ASK:
0.000		VOLUME:
314.0K
CHG(%):
4.04		PREV:
2.230		LOW:
2.125		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 252.2602.2602.1252.140314.0K
06 Nov 252.3102.3402.1702.2302.85M
05 Nov 252.3402.4272.2902.330851.3K
04 Nov 252.5502.5702.3302.3301.28M
03 Nov 252.7702.7702.5702.6001.2M
31 Oct 252.6702.8092.6202.7301.25M
30 Oct 252.7102.7502.6002.6401.03M
29 Oct 252.8702.9002.7102.7301.09M
28 Oct 253.0803.1002.8302.8701.44M
27 Oct 253.0503.1503.0053.1001.91M

COMPANY PROFILE

Name:Perspective Therapeutics Inc
About:Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Sector:Healthcare
Address:2401 Elliott Avenue, Seattle, WA, United States, 98121
Website:https://www.perspectivetherapeutics.com
CIK:0000728387
ISIN:US46489V3024
FIGI:BBG000BG5HT7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.92 
Forward P/E:-2.44 
PEG Ratio:-0.03 
Price to Sales:158.15 
Price to Book:0.74 
Operating Margin:-82.89 
Return on Assets:-0.15 
Return on Equity:-0.31 
EPS Ratio:-1.37 
Revenue:1.24M 
Shares:74.26M 
Market Cap:158.92M 

TECHNICAL INDICATORS

MA5:2.338.8%
MA10:2.5720.2%
MA20:3.2451.4%
MA50:3.3757.4%
MA100:3.5867.2%
MA200:3.1145.3%
RSI14:18.73 
WPR14:-100.00 
MTM14:-0.96
ROC14:-0.31 
ATR:0.22 
Week High:2.8131.3%
Week Low:2.130.7%
Month High:5.39151.8%
Month Low:2.1345.3%
Year High:12.42480.4%
Year Low:1.6033.8%
Volatility:80.01 

RECENT SPLITS

Date Ratio
17 Jun 20241-10